-
1
-
-
0027197245
-
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
-
Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4
-
(1993)
Nature
, vol.362
, pp. 841-844
-
-
Kim, K.J.1
Li, B.2
Winer, J.3
-
2
-
-
0029006696
-
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
-
Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-6
-
(1995)
Nature
, vol.376
, pp. 62-66
-
-
Shalaby, F.1
Rossant, J.2
Yamaguchi, T.P.3
-
3
-
-
0032707249
-
A requirement for neuropilin-1 in embryonic vessel formation
-
Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999;126:4895-902
-
(1999)
Development
, vol.126
, pp. 4895-4902
-
-
Kawasaki, T.1
Kitsukawa, T.2
Bekku, Y.3
-
4
-
-
0029021660
-
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
-
Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70
-
(1995)
Nature
, vol.376
, pp. 66-70
-
-
Fong, G.H.1
Rossant, J.2
Gertsenstein, M.3
Breitman, M.L.4
-
5
-
-
0033387447
-
Angiogenesis in ischemic disease
-
Marti HH, Risau W. Angiogenesis in ischemic disease. Thromb Haemost 1999;82 (Suppl 1):44-52
-
(1999)
Thromb Haemost
, vol.82
, pp. 44-52
-
-
Marti, H.H.1
Risau, W.2
-
6
-
-
0035062394
-
The splice variants of vascular endothelial growth factor (VEGF) and their receptors
-
Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114:853-65
-
(2001)
J Cell Sci
, vol.114
, pp. 853-865
-
-
Robinson, C.J.1
Stringer, S.E.2
-
7
-
-
0029953517
-
Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1
-
Ryuto M, Ono M, Izumi H, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996;271:28220-8
-
(1996)
J Biol Chem
, vol.271
, pp. 28220-28228
-
-
Ryuto, M.1
Ono, M.2
Izumi, H.3
-
8
-
-
0029072011
-
Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia
-
Stavri GT, Zachary IC, Baskerville PA, et al. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 1995;92:11-14
-
(1995)
Circulation
, vol.92
, pp. 11-14
-
-
Stavri, G.T.1
Zachary, I.C.2
Baskerville, P.A.3
-
9
-
-
0028870050
-
Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
-
Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995;92:768-72
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 768-772
-
-
Shweiki, D.1
Neeman, M.2
Itin, A.3
Keshet, E.4
-
10
-
-
0029761644
-
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
-
Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13
-
(1996)
Mol Cell Biol
, vol.16
, pp. 4604-4613
-
-
Forsythe, J.A.1
Jiang, B.H.2
Iyer, N.V.3
-
11
-
-
0031000736
-
A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development
-
Ema M, Taya S, Yokotani N, et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997;94:4273-8
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 4273-4278
-
-
Ema, M.1
Taya, S.2
Yokotani, N.3
-
12
-
-
0029117223
-
Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells
-
Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995;270:19761-6
-
(1995)
J Biol Chem
, vol.270
, pp. 19761-19766
-
-
Ikeda, E.1
Achen, M.G.2
Breier, G.3
Risau, W.4
-
13
-
-
0031869662
-
Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia
-
Stein I, Itin A, Einat P, et al. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 1998;18:3112-19
-
(1998)
Mol Cell Biol
, vol.18
, pp. 3112-3119
-
-
Stein, I.1
Itin, A.2
Einat, P.3
-
14
-
-
0032515047
-
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
-
Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-43
-
(1998)
J Biol Chem
, vol.273
, pp. 30336-30343
-
-
Gerber, H.P.1
McMurtrey, A.2
Kowalski, J.3
-
15
-
-
79960370663
-
EGFR genomic alterations in cancer: Prognostic and predictive values
-
Bronte G, Terrasi M, Rizzo S, et al. EGFR genomic alterations in cancer: prognostic and predictive values. Front Biosci (Elite Ed) 2011;3:879-87
-
(2011)
Front Biosci (Elite Ed)
, vol.3
, pp. 879-887
-
-
Bronte, G.1
Terrasi, M.2
Rizzo, S.3
-
16
-
-
77949883874
-
The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway
-
Russo A, Rizzo S, Bronte G, et al. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology 2009;77(Suppl 1):57-68
-
(2009)
Oncology
, vol.77
, pp. 57-68
-
-
Russo, A.1
Rizzo, S.2
Bronte, G.3
-
17
-
-
83655211666
-
Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer
-
Poole EM, Curtin K, Hsu L, et al. Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. Int J Mol Epidemiol Genet 2011;2:300-15
-
(2011)
Int J Mol Epidemiol Genet
, vol.2
, pp. 300-315
-
-
Poole, E.M.1
Curtin, K.2
Hsu, L.3
-
18
-
-
33746257209
-
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
-
Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19
-
(2006)
Nat Rev Genet
, vol.7
, pp. 606-619
-
-
Engelman, J.A.1
Luo, J.2
Cantley, L.C.3
-
19
-
-
77949888718
-
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma
-
Silvestris N, Tommasi S, Petriella D, et al. The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. Oncology 2009;77(Suppl 1):69-74
-
(2009)
Oncology
, vol.77
, pp. 69-74
-
-
Silvestris, N.1
Tommasi, S.2
Petriella, D.3
-
20
-
-
20544478429
-
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
-
Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705
-
(2005)
J Clin Oncol
, vol.23
, pp. 3697-3705
-
-
Kabbinavar, F.F.1
Schulz, J.2
McCleod, M.3
-
21
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
22
-
-
78649744892
-
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy?
-
Rizzo S, Bronte G, Fanale D, et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 2010;36(Suppl 3):S56-61
-
(2010)
Cancer Treat Rev
, vol.36
, pp. S56-S61
-
-
Rizzo, S.1
Bronte, G.2
Fanale, D.3
-
23
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E.1
Köhne, C.H.2
Láng, I.3
-
24
-
-
84883680951
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
-
Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34
-
(2013)
N Engl J Med
, vol.369
, pp. 1023-1034
-
-
Douillard, J.Y.1
Oliner, K.S.2
Siena, S.3
-
25
-
-
59949091448
-
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
-
Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71
-
(2009)
J Clin Oncol
, vol.27
, pp. 663-671
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
-
26
-
-
84861432557
-
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study
-
Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30:1755-62
-
(2012)
J Clin Oncol
, vol.30
, pp. 1755-1762
-
-
Tveit, K.M.1
Guren, T.2
Glimelius, B.3
-
27
-
-
79959337678
-
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial
-
Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14
-
(2011)
Lancet
, vol.377
, pp. 2103-2114
-
-
Maughan, T.S.1
Adams, R.A.2
Smith, C.G.3
-
28
-
-
84880338271
-
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting
-
Rolfo C, Russo A, Santini D, et al. Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting. Expert Opin Ther Targets 2013;17:869-71
-
(2013)
Expert Opin Ther Targets
, vol.17
, pp. 869-871
-
-
Rolfo, C.1
Russo, A.2
Santini, D.3
-
29
-
-
84871720057
-
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial
-
Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37
-
(2013)
Lancet Oncol
, vol.14
, pp. 29-37
-
-
Bennouna, J.1
Sastre, J.2
Arnold, D.3
-
30
-
-
84865553918
-
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance?
-
Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol 2012;23:2313-18
-
(2012)
Ann Oncol
, vol.23
, pp. 2313-2318
-
-
Santini, D.1
Vincenzi, B.2
Addeo, R.3
-
31
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
-
32
-
-
84867047384
-
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
-
Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506
-
(2012)
J Clin Oncol
, vol.30
, pp. 3499-3506
-
-
Van Cutsem, E.1
Tabernero, J.2
Lakomy, R.3
-
33
-
-
84899940235
-
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer
-
Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:107-16
-
(2014)
Ann Oncol
, vol.25
, pp. 107-116
-
-
Peeters, M.1
Price, T.J.2
Cervantes, A.3
-
34
-
-
84872921660
-
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial
-
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12
-
(2013)
Lancet
, vol.381
, pp. 303-312
-
-
Grothey, A.1
Van Cutsem, E.2
Sobrero, A.3
-
35
-
-
84882937605
-
DTe. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). ASCO Annual Meeting; 2013; Chicago
-
Heinemann V, Von Weikersthal LF, et al. DTe. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). ASCO Annual Meeting; 2013; Chicago. J Clin Oncol 2013
-
(2013)
J Clin Oncol
-
-
Heinemann, V.1
Von Weikersthal, L.F.2
-
36
-
-
33745547767
-
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
-
Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9
-
(2006)
J Clin Oncol
, vol.24
, pp. 2903-2909
-
-
Wagner, A.D.1
Grothe, W.2
Haerting, J.3
-
37
-
-
84863294022
-
Effect of HER-2/neu over-expression on prognosis in gastric cancer: A meta-analysis
-
Wang S, Zheng G, Chen L, Xiong B. Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev 2011;12:1417-23
-
(2011)
Asian Pac J Cancer Prev
, vol.12
, pp. 1417-1423
-
-
Wang, S.1
Zheng, G.2
Chen, L.3
Xiong, B.4
-
38
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
-
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
-
(2010)
Lancet
, vol.376
, pp. 687-697
-
-
Bang, Y.J.1
Van Cutsem, E.2
Feyereislova, A.3
-
39
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
40
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
-
41
-
-
84867871965
-
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits
-
Chiu J, Tang YF, Yao TJ, et al. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 2012;118:5293-301
-
(2012)
Cancer
, vol.118
, pp. 5293-5301
-
-
Chiu, J.1
Tang, Y.F.2
Yao, T.J.3
-
42
-
-
84859699041
-
High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event
-
Knosel T, Chen Y, Altendorf-Hofmann A, et al. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event. J Cancer Res Clin Oncol 2012;138:397-403
-
(2012)
J Cancer Res Clin Oncol
, vol.138
, pp. 397-403
-
-
Knosel, T.1
Chen, Y.2
Altendorf-Hofmann, A.3
-
44
-
-
84871132726
-
Systemic treatment of neuroendocrine tumors with hepatic metastases
-
Demirkan BH, Eriksson B. Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol 2012;23:427-37
-
(2012)
Turk J Gastroenterol
, vol.23
, pp. 427-437
-
-
Demirkan, B.H.1
Eriksson, B.2
-
45
-
-
79851482955
-
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
-
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
-
(2011)
N Engl J Med
, vol.364
, pp. 501-513
-
-
Raymond, E.1
Dahan, L.2
Raoul, J.L.3
-
46
-
-
79851500081
-
Everolimus for advanced pancreatic neuroendocrine tumors
-
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23
-
(2011)
N Engl J Med
, vol.364
, pp. 514-523
-
-
Yao, J.C.1
Shah, M.H.2
Ito, T.3
-
47
-
-
79960252581
-
Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): Results from the RADIANT-3 trial. ASCO Annual Meeting Abstracts
-
Pommier RF, Wolin EM, Panneerselvam A. Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): Results from the RADIANT-3 trial. ASCO Annual Meeting Abstracts, J Clin Oncol 2011. 29(15 Suppl); 4103
-
(2011)
J Clin Oncol
, vol.29
, Issue.15
, pp. 4103
-
-
Pommier, R.F.1
Wolin, E.M.2
Panneerselvam, A.3
-
48
-
-
79960206612
-
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. 2011 ASCO Annual Meeting Abstracts
-
Shah MH, Lombard-Bohas C, Ito T, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. 2011 ASCO Annual Meeting Abstracts, J Clin Oncol 2011. 29(15 Suppl); 4010
-
(2011)
J Clin Oncol
, vol.29
, Issue.15
, pp. 4010
-
-
Shah, M.H.1
Lombard-Bohas, C.2
Ito, T.3
-
49
-
-
80052197143
-
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
-
Altomare I, Bendell JC, Bullock KE, et al. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 2011;16:1131-7
-
(2011)
Oncologist
, vol.16
, pp. 1131-1137
-
-
Altomare, I.1
Bendell, J.C.2
Bullock, K.E.3
-
50
-
-
5144229336
-
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting
-
Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004;10:6487-501
-
(2004)
Clin Cancer Res
, vol.10
, pp. 6487-6501
-
-
Matar, P.1
Rojo, F.2
Cassia, R.3
-
51
-
-
84862987061
-
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer
-
Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol 2012;30:1505-12
-
(2012)
J Clin Oncol
, vol.30
, pp. 1505-1512
-
-
Weickhardt, A.J.1
Price, T.J.2
Chong, G.3
-
52
-
-
84876089340
-
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: A randomized, phase III trial
-
Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 2013;31:1341-7
-
(2013)
J Clin Oncol
, vol.31
, pp. 1341-1347
-
-
Carrato, A.1
Swieboda-Sadlej, A.2
Staszewska-Skurczynska, M.3
-
53
-
-
84877098937
-
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: The RESPECT trial
-
Tabernero J, Garcia-Carbonero R, Cassidy J, et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res 2013;19:2541-50
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2541-2550
-
-
Tabernero, J.1
Garcia-Carbonero, R.2
Cassidy, J.3
-
54
-
-
84877064638
-
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer
-
Wolpin BM, Ng K, Zhu AX, et al. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 2013;18:377-8
-
(2013)
Oncologist
, vol.18
, pp. 377-378
-
-
Wolpin, B.M.1
Ng, K.2
Zhu, A.X.3
-
55
-
-
80054730200
-
Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)
-
Cheng AL, Kang Y, Lin D, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011;29(Suppl); abstr 4000
-
(2011)
J Clin Oncol
, vol.29
-
-
Cheng, A.L.1
Kang, Y.2
Lin, D.3
-
56
-
-
84885894561
-
Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
-
Cainap C, Qin S, Huang WT, et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2013;30(Suppl 34); abstr 249
-
(2013)
J Clin Oncol
, vol.30
-
-
Cainap, C.1
Qin, S.2
Huang, W.T.3
-
57
-
-
84885188451
-
Brivanib (BRI) versus sorafenib (SOR) as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma (HCC): Results from the phase 3 BRISK-FL study
-
Johnson P, Qin S, Park JW, et al. Brivanib (BRI) versus sorafenib (SOR) as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma (HCC): results from the phase 3 BRISK-FL study. In 63rd Annual Meeting of the American Association for the Study of Liver Disease 2012; abstr LB-6
-
(2012)
63rd Annual Meeting of the American Association for the Study of Liver Disease
-
-
Johnson, P.1
Qin, S.2
Park, J.W.3
-
58
-
-
84898912823
-
Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: Results from the phase 3 BRISK-PS study
-
Llovet JM, Decaens T, Raoul JL, et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. In 47th International Liver Congress (EASL) 2012; abstr 1398
-
(2012)
47th International Liver Congress (EASL)
-
-
Llovet, J.M.1
Decaens, T.2
Raoul, J.L.3
-
59
-
-
84872301160
-
SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC)
-
Zhu AX, Rosmorduc O, Evans J, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). In ESMO Congress 2012; abstr 917
-
ESMO Congress 2012
-
-
Zhu, A.X.1
Rosmorduc, O.2
Evans, J.3
-
60
-
-
84911395834
-
Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC)
-
Chelis L, Deftereos S, Xenidis N, et al. Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC). J Clin Oncol 2012;30(Suppl); abstr e14567
-
(2012)
J Clin Oncol
, vol.30
-
-
Chelis, L.1
Deftereos, S.2
Xenidis, N.3
-
61
-
-
33750618860
-
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
-
Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-7
-
(2006)
J Clin Oncol
, vol.24
, pp. 4922-4927
-
-
Dragovich, T.1
McCoy, S.2
Fenoglio-Preiser, C.M.3
-
62
-
-
80052439302
-
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
-
Wainberg ZA, Lin LS, DiCarlo B, et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011;105:760-5
-
(2011)
Br J Cancer
, vol.105
, pp. 760-765
-
-
Wainberg, Z.A.1
Lin, L.S.2
DiCarlo, B.3
-
63
-
-
77649085714
-
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer
-
Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010;5:229-35
-
(2010)
J Thorac Oncol
, vol.5
, pp. 229-235
-
-
Rodriguez, C.P.1
Adelstein, D.J.2
Rice, T.W.3
-
64
-
-
38649093257
-
S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer
-
Iqbal S, Goldman B, Lenz HJ, et al. S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 2007;25; Abstract 4621
-
(2007)
J Clin Oncol
, vol.25
-
-
Iqbal, S.1
Goldman, B.2
Lenz, H.J.3
-
65
-
-
77953453066
-
Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses
-
Hecht JR, Urba SG, Koehler M, et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses. In Gastrointestinal Cancers Symposium (ASCO) 2008; Abstract 43
-
Gastrointestinal Cancers Symposium (ASCO) 2008
-
-
Hecht, J.R.1
Urba, S.G.2
Koehler, M.3
-
66
-
-
84882418636
-
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) inHER2-positive advanced or metastatic gastric, esophageal, or gastro-esophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial
-
Hecht J, Bang YJ, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) inHER2-positive advanced or metastatic gastric, esophageal, or gastro-esophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial. J Clin Oncol 2013;31(Suppl l); abstr LBA4001
-
(2013)
J Clin Oncol
, vol.31
-
-
Hecht, J.1
Bang, Y.J.2
Qin, S.3
-
67
-
-
84911456898
-
The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries
-
Bang Y-J. The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries. J Clin Oncol 2012;30(suppl 34; abstr 11
-
(2012)
J Clin Oncol
, vol.30
-
-
Bang, Y.-J.1
-
68
-
-
79957864676
-
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: A prospective multi-center biomarker-oriented phase II study
-
Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011;22:1358-66
-
(2011)
Ann Oncol
, vol.22
, pp. 1358-1366
-
-
Moehler, M.1
Mueller, A.2
Trarbach, T.3
-
69
-
-
79957539777
-
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
-
Kim C, Lee JL, Ryu MH, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011;29:366-73
-
(2011)
Invest New Drugs
, vol.29
, pp. 366-373
-
-
Kim, C.1
Lee, J.L.2
Ryu, M.H.3
-
70
-
-
84881099408
-
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study
-
Richards D, Kocs DM, Spira AI, et al. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. Eur J Cancer 2013;49:2823-31
-
(2013)
Eur J Cancer
, vol.49
, pp. 2823-2831
-
-
Richards, D.1
Kocs, D.M.2
Spira, A.I.3
-
71
-
-
84876951761
-
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial
-
Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:490-9
-
(2013)
Lancet Oncol
, vol.14
, pp. 490-499
-
-
Lordick, F.1
Kang, Y.K.2
Chung, H.C.3
-
72
-
-
84876992498
-
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial
-
Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:481-9
-
(2013)
Lancet Oncol
, vol.14
, pp. 481-489
-
-
Waddell, T.1
Chau, I.2
Cunningham, D.3
-
73
-
-
33846629672
-
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
-
Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-6
-
(2006)
J Clin Oncol
, vol.24
, pp. 5201-5206
-
-
Shah, M.A.1
Ramanathan, R.K.2
Ilson, D.H.3
-
74
-
-
79952355358
-
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma
-
Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29:868-74
-
(2011)
J Clin Oncol
, vol.29
, pp. 868-874
-
-
Shah, M.A.1
Jhawer, M.2
Ilson, D.H.3
-
75
-
-
80053573446
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study
-
Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76
-
(2011)
J Clin Oncol
, vol.29
, pp. 3968-3976
-
-
Ohtsu, A.1
Shah, M.A.2
Van Cutsem, E.3
-
76
-
-
84864577467
-
Survival analysis according todisease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (BEV) or placebo in patients with advanced gastric cancer
-
Shah MA, Van Cutsem E, Kang YK, et al. Survival analysis according todisease subtype in AVAGAST: first-line capecitabine and cisplatin plus bevacizumab (BEV) or placebo in patients with advanced gastric cancer. ASCO Meet Abstr 2012; 30(Suppl 4):5
-
(2012)
ASCO Meet Abstr
, vol.30
, pp. 5
-
-
Shah, M.A.1
Van Cutsem, E.2
Kang, Y.K.3
-
77
-
-
84863897798
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial
-
Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30:2119-27
-
(2012)
J Clin Oncol
, vol.30
, pp. 2119-2127
-
-
Van Cutsem, E.1
De Haas, S.2
Kang, Y.K.3
-
78
-
-
84892852372
-
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial
-
Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9
-
(2014)
Lancet
, vol.383
, pp. 31-39
-
-
Fuchs, C.S.1
Tomasek, J.2
Yong, C.J.3
-
79
-
-
84906571698
-
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)
-
Wilke H, Van Cutsem E, Oh SC, et al. RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). In 2014 Gastrointestinal Cancers Symposium; Abstract No: LBA7
-
2014 Gastrointestinal Cancers Symposium
-
-
Wilke, H.1
Van Cutsem, E.2
Oh, S.C.3
-
81
-
-
44449151030
-
Drug development of MET inhibitors: Targeting oncogene addiction and expedience
-
Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 504-516
-
-
Comoglio, P.M.1
Giordano, S.2
Trusolino, L.3
-
82
-
-
84875025156
-
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC)
-
Yau TC, Sukeepaisamjaroen W, Chao Y, et al. A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2012;30(Suppl); abstr 4108
-
(2012)
J Clin Oncol
, vol.30
-
-
Yau, T.C.1
Sukeepaisamjaroen, W.2
Chao, Y.3
-
83
-
-
84871721240
-
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study
-
Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013;14:55-63
-
(2013)
Lancet Oncol
, vol.14
, pp. 55-63
-
-
Santoro, A.1
Rimassa, L.2
Borbath, I.3
-
84
-
-
84872549428
-
Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)
-
Verslype C, Cohn AL, Kelley RK, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012; 30(Suppl); abstr 4007
-
(2012)
J Clin Oncol
, vol.30
-
-
Verslype, C.1
Cohn, A.L.2
Kelley, R.K.3
-
85
-
-
79954471845
-
Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target
-
Lee J, Seo JW, Jun HJ, et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011;25:1517-24
-
(2011)
Oncol Rep
, vol.25
, pp. 1517-1524
-
-
Lee, J.1
Seo, J.W.2
Jun, H.J.3
-
86
-
-
84875035582
-
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer
-
Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013;8:e54014
-
(2013)
PLoS One
, vol.8
, pp. e54014
-
-
Shah, M.A.1
Wainberg, Z.A.2
Catenacci, D.V.3
-
87
-
-
84870511276
-
Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R AMG 102) or placebo(P) in combination with epirubicin, cisplatin, and capecitabine (ECX) inpatients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer
-
Oliner KS, Tang R, Anderson A, et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R AMG 102) or placebo(P) in combination with epirubicin, cisplatin, and capecitabine (ECX) inpatients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. ASCO Meeting 2012;30(Suppl 15); Abstr 4005
-
(2012)
ASCO Meeting
, vol.30
-
-
Oliner, K.S.1
Tang, R.2
Anderson, A.3
-
89
-
-
79959214127
-
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma
-
O'Neil BH, Goff LW, Kauh JS, et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2011;29:2350-6
-
(2011)
J Clin Oncol
, vol.29
, pp. 2350-2356
-
-
O'Neil, B.H.1
Goff, L.W.2
Kauh, J.S.3
-
90
-
-
84885664750
-
A phase I/II study of AZD6244 in combination with sorafenib in advanced hepatocellular carcinoma
-
Choo SP, Ng QS, Chen WJJ, et al. A phase I/II study of AZD6244 in combination with sorafenib in advanced hepatocellular carcinoma. J Clin Oncol 2012;30(Suppl); abstr 4100
-
(2012)
J Clin Oncol
, vol.30
-
-
Choo, S.P.1
Ng, Q.S.2
Chen, W.J.J.3
-
91
-
-
84868334005
-
Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC)
-
Abou-Alfa GK, Gansukh B, Chou JF, et al. Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC). J Clin Oncol 2011; 29(Suppl 4); abstr 4043
-
(2011)
J Clin Oncol
, vol.29
-
-
Abou-Alfa, G.K.1
Gansukh, B.2
Chou, J.F.3
-
92
-
-
79955475247
-
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
-
Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011;306:171-9
-
(2011)
Cancer Lett
, vol.306
, pp. 171-179
-
-
Barok, M.1
Tanner, M.2
Koninki, K.3
Isola, J.4
|